Vanda's NEREUS cut GLP-1 vomiting by 27% in a Phase III trial
Vomiting hit 43% on tradipitant versus 58.5% on placebo after a single semaglutide dose. Vanda plans to seek FDA approval for the new use.
Recap by typeshit. Full story at BioBuzz.
Vomiting hit 43% on tradipitant versus 58.5% on placebo after a single semaglutide dose. Vanda plans to seek FDA approval for the new use.
Recap by typeshit. Full story at BioBuzz.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
She says slower stomach emptying on GLP-1s can affect some psychiatric meds, and that while not every combination matters, some deserve closer monitoring.
Men's Journal reports the coroner's findings on the cause of Norton's death, with the dose detail coming from the coroner rather than earlier speculation.
Loading…